Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study
Authors
M. Beylot‐Barry (ORCID: https://orcid.org/0000-0001-6150-1229)
Marcus O. Butler (ORCID: https://orcid.org/0000-0002-9840-7057)
Ana Arance (ORCID: https://orcid.org/0000-0003-2896-1957)
Michele Maio (ORCID: https://orcid.org/0000-0002-0323-6321)
Paolo A. Ascierto (ORCID: https://orcid.org/0000-0002-8322-475X)
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study
M. Beylot‐Barry, Marcus O. Butler, Ana Arance, Michele Maio et al.
Citations
5 citations
Journal
American Journal of Clinical Dermatology
Topics
Polyomavirus and related diseases
Field-Weighted Citation Impact (FWCI)
1.41
article
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study
M. Beylot‐Barry, Marcus O. Butler, Ana Arance, Michele Maio, Paolo A. Ascierto, Vanna Chiarion‐Sileni, Philippe Saïag, Michel De Pontville, Clemens Krepler, Debasmita Das, Enrique Espinosa, Lisa Villabona, Dmitri Grebennik, Max Levin, Laurent Mortier, Francesca Spada, Ben Lawrence, Jaume Capdevila, Alfonso Berrocal, Mahtab Samimi
article en
5 citations
Abstract
No abstract available for this paper.
Publication Tag
American Journal of Clinical DermatologyVol. 25(6)
Institutions
University of Siena (IT), Université de Tours (FR), Hebron University (PS), Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Karolinska University Hospital (SE), University of Auckland (NZ), Inserm (FR), University of Toronto (CA), Université de Lille (FR), Université Paris-Saclay (FR), Hospital Universitario La Paz (ES), Sahlgrenska University Hospital (SE), Auckland City Hospital (NZ), Canada Research Chairs (CA), Centre Hospitalier Universitaire de Bordeaux (FR), Centre Hospitalier Universitaire de Lille (FR), Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (FR), Centre Hospitalier Universitaire de Tours (FR), Assistance Publique – Hôpitaux de Paris (FR), Vall d'Hebron Institut de Recerca (ES), Bordeaux Population Health (FR), Istituto Oncologico Veneto (IT), Centre Hospitalier Universitaire de Caen Normandie (FR), Hospital Clínic de Barcelona (ES), Vall d'Hebron Hospital Universitari (ES), Hospital General Universitario De Valencia (ES), Hôpital Ambroise-Paré (FR), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), Hospital Universitari de Vic (ES), Ospedale San Giuseppe (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Centro de Investigación Biomédica en Red de Cáncer (ES), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Auckland Park Hospital (GB), Vall d'Hebron Institute of Oncology (ES), BoRdeaux Institute of onCology (FR), European Institute of Oncology (IT), Universidad Autónoma de Madrid (ES), University of Gothenburg (SE), Université de Caen Normandie (FR)